Literature DB >> 31934202

Histologic characteristics and prognosis of lung mixed squamous cell and glandular papilloma: six case reports.

Fei Li1, Ming He1, Fang Li2, Yong Li1, Yuan Song3.   

Abstract

Lung mixed squamous cell and glandular papilloma (LMSCGP) has no clear signs, clinical symptoms, or imaging features; thus, its diagnosis primarily relies on post-resection histology and immunohistochemistry. Therefore, in this work six case reports are described to review the clinicopathologic characteristics, diagnosis, treatment, and prognosis. Here, we report the clinical symptoms, imaging features, pathologic characteristics, and follow-up data of six LMSCGP patients. Among the 6 patients, 4 were males and 2 were females, with a mean age of 52.7 years (39-67 years). These patients accounted for 0.0827% of patients who underwent thoracic surgery in the same period (6/7357). Preoperative diagnosis indicated cancer or most likely cancer in 3 patients, benign lesions in 3 patients, and bronchial adenoma in 1 patient. All 6 patients underwent surgery, consisting of wedge resection in 3 patients and lobectomy in the other 3 patients. Hilar lymph node metastasis was not identified during postoperative pathologic diagnosis.
Conclusion: LMSCGP is a rare lung tumor with a certain heterogeneity that makes definite preoperative diagnosis difficult. Complete surgical resection is the preferred treatment choice and results in a good prognosis in most cases. IJCEP
Copyright © 2019.

Entities:  

Keywords:  Mixed squamous cell glandular papilloma; lung tumor; prognosis; surgery

Year:  2019        PMID: 31934202

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  1 in total

1.  Multiple Primary Lung Tumors of Different Pathological Types Including Squamous Cell Carcinoma, Adenocarcinoma, and Mixed Squamous Cell and Glandular Papilloma: A Case Report.

Authors:  Xiaojing Wang; Haifeng Liu; Dongjie Zhai; Yanan Qin; Chuifeng Fan; Di Zhang
Journal:  Onco Targets Ther       Date:  2022-01-06       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.